Show simple item record

dc.contributor.authorSimons, Gwenda
dc.contributor.authorVeldwijk, Jorien
dc.contributor.authorDiSantostefano, Rachael L
dc.contributor.authorEnglbrecht, Matthias
dc.contributor.authorRadawski, Christine
dc.contributor.authorBywall, Karin Schölin
dc.contributor.authorValor Méndez, Larissa
dc.contributor.authorHauber, Brett
dc.contributor.authorRaza, Karim
dc.contributor.authorFalahee, Marie
dc.date.accessioned2023-06-20T10:15:50Z
dc.date.available2023-06-20T10:15:50Z
dc.date.issued2023-02
dc.identifier.citationSimons G, Veldwijk J, DiSantostefano RL, Englbrecht M, Radawski C, Bywall KS, Valor Méndez L, Hauber B, Raza K, Falahee M. Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania. Rheumatology (Oxford). 2023 Feb 1;62(2):596-605. doi: 10.1093/rheumatology/keac397en_US
dc.identifier.eissn1462-0332
dc.identifier.doi10.1093/rheumatology/keac397
dc.identifier.pmid36068022
dc.identifier.urihttp://hdl.handle.net/20.500.14200/1052
dc.description.abstractObjective: To quantify preferences for preventive therapies for rheumatoid arthritis (RA) across three countries. Methods: A web-based survey including a discrete choice experiment was administered to adults recruited via survey panels in the UK, Germany and Romania. Participants were asked to assume they were experiencing arthralgia and had a 60% chance of developing RA in the next 2 years and completed 15 choices between no treatment and two hypothetical preventive treatments. Treatments were defined by six attributes (effectiveness, risks and frequency/route of administration) with varying levels. Participants also completed a choice task with fixed profiles reflecting subjective estimates of candidate preventive treatments. Latent class models (LCMs) were conducted and the relative importance of attributes, benefit-risk trade-offs and predicted treatment uptake was subsequently calculated. Results: Completed surveys from 2959 participants were included in the analysis. Most participants preferred treatment over no treatment and valued treatment effectiveness to reduce risk more than other attributes. A five-class LCM best fitted the data. Country, perceived risk of RA, health literacy and numeracy predicted class membership probability. Overall, the maximum acceptable risk for a 40% reduction in the chance of getting RA (60% to 20%) was 21.7%, 19.1% and 2.2% for mild side effects, serious infection and serious side effects, respectively. Predicted uptake of profiles reflecting candidate prevention therapies differed across classes. Conclusion: Effective preventive pharmacological treatments for RA were acceptable to most participants. The relative importance of treatment attributes and likely uptake of fixed treatment profiles were predicted by participant characteristics.en_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.subjectRheumatologyen_US
dc.titlePreferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania.en_US
dc.typeArticle
dc.source.journaltitleRheumatology
rioxxterms.versionNAen_US
dc.contributor.trustauthorRaza, Karim
dc.contributor.departmentRheumatologyen_US
dc.contributor.roleMedical and Dentalen_US
dc.contributor.affiliationUniversity of Birmingham; Erasmus University Rotterdam; Utrecht University; Sandwell and West Birmingham NHS Trust; et al.en_US
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record